R. Gregory Bociek

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

Kai Fu, Dennis D. Weisenburger, William W.L. Choi et al. · Journal of Clinical Oncology · 2008 · 336 citations · Full text

Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Susan O’Brien, Joseph O. Moore, Thomas E. Boyd et al. · Journal of Clinical Oncology · 2007 · 298 citations

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group

G.B. Ryan, Giovanni Martinelli, Marion Kuper‐Hommel et al. · Annals of Oncology · 2007 · 249 citations · Full text

Prognostic Factors, Lymphoid Neoplasia, Breast Oncology +4

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas et al. · Blood · 2018 · 246 citations · Full text

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

Nancy L. Bartlett, Anas Younes, Matthew Carabasi et al. · Blood · 2007 · 196 citations · Full text